CofixRx, LLC – FDA Warning Letter, Jan 4, 2022
On April 5, 2022, the FDA issued a Warning Letter to the manufacturer of CofixRX Nasal Spray following a January 4, 2022, review of their website (https://cofixrx.com) and product labeling. The FDA determined that CofixRX Nasal Spray is an unapproved new drug, sold in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and a misbranded drug under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee).
The product is marketed with claims to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions, such as "DESTROYS SARS CoV-2 and other COLD & FLU viruses in 15 seconds" and "offers up to 8 hours of protection." These claims render it a "drug" under section 201(g)(1)(B) and (C) of the FD&C Act. As a "new drug," it is not generally recognized as safe and effective (GRASE) for its intended uses, and no FDA-approved application exists.
Furthermore, CofixRX Nasal Spray does not conform to the conditions for marketing nonprescription drugs without an
ID · 2fed8cdf-b429-4581-b3f6-ad5c04ebdf59
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.